Implantable Drug-Device Combinations for Pituitary Gland Treatment
Summary
The USPTO published patent application US20260096905A1 covering implantable drug-device combinations designed for direct delivery of therapeutic drugs to the pituitary gland. The invention includes a cap, stem, and therapeutically effective drug, with the device acting as a barrier between the sella turcica and sphenoid sinus to trap drug substances and prevent premature escape into cerebrospinal fluid, thereby reducing systemic toxicity.
What changed
The USPTO published patent application US20260096905A1 for implantable drug-device combinations used in pituitary gland treatment. The invention comprises a cap, a stem, and a drug therapeutically effective for pituitary gland disorders, configured to act as a barrier between the sella turcica and sphenoid sinus to confine drug release to the target site and reduce systemic toxicity.
Manufacturers developing drug delivery devices for neurological or endocrine applications, as well as pharmaceutical companies exploring targeted pituitary therapies, should review the patent claims for potential licensing needs, design-around considerations, or partnership opportunities. The barrier mechanism described could influence future device design approaches for targeted CNS drug delivery.
What to do next
- Monitor for patent issuance and assess freedom-to-operate implications for pituitary drug delivery devices
- Review patent claims for potential licensing or design-around opportunities
- Evaluate applicability of device and drug claims to product development pipelines
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMPLANTABLE DRUG-DEVICE COMBINATIONS, AND RELATED METHODS OF TREATMENT
Application US20260096905A1 Kind: A1 Apr 09, 2026
Inventors
Patrick J. Fitzgerald
Abstract
Provided are drug-device combinations and methods used for direct delivery of therapeutic drugs to the pituitary gland, wherein the drug-device combination also acts as a barrier between a sella turcica (pituitary fossa) and a sphenoid sinus to effectively trap or confine the drug substance within the sella turcica to prevent its premature escape away into the CSF from the target pituitary; thereby reducing or eliminating systemic toxicity of the drug substance. The drug-device combination includes a cap, a stem, a drug that is therapeutically effective for a pituitary gland disorder.
CPC Classifications
A61F 2/46 A61L 27/18 A61L 27/227 A61F 2002/30062 A61F 2002/30677 A61L 2300/43 A61L 2300/432 A61L 2300/622 A61L 2300/624
Filing Date
2025-10-07
Application No.
19352375
Related changes
Get daily alerts for USPTO Patent Applications - Prosthetics (A61F)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Prosthetics (A61F) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.